An immunohistochemistry study of tissue bcl-2 expression and its serum levels in breast cancer patients.
Variations in Bcl-2 expression have been reported in malignant tissues with various origins. In the case of breast cancer, the involvement of Bcl-2 overexpression in tumorigenicity and metastatic potential has been stated. However, association of tumor progression and loss of Bcl-2 in tumor cells is also being investigated. Augmentation of plasma levels of Bcl-2 was speculated in patients with metastatic breast cancer. The present study was designed to evaluate Bcl-2 protein expression in breast tumor paraffin-embedded fixed tissue and sought to investigate association with the Bcl-2 protein release in patient serum, as well as its relationship with clinicopathological features. Immunohistochemistry methods were applied to breast tumor sections from 35 surgically removed patient samples and 35 normal or benign tissue samples. The sera taken from both the patient and control groups were tested for soluble Bcl-2 (BMs244/3 Kit) using ELISA technique. Tumor type, grade, and size and patient menopause status and age were considered to analyze the association between these parameters. The analysis shows that 67.6% of the tumor sections were positive for Bcl-2 expression and 32.4% negative. Bcl-2 protein expression was positive in 57.1% of normal/benign section tumors. The Bcl-2 serum levels were 3.6 +/- 1.1 ng/mL in the patient group and 3.23 +/- 0.06 ng/mL in the control group. A weak correlation was found between Bcl-2 serum levels and tissue expression of the molecules (r= 0.382, P= 0.049). A negative association (but not statically significant) was obtained between Bcl-2 and low-grade stages (r=-0.375, P= 0.08). A positive and significant correlation was shown between Bcl-2 and menopause (r= 0.523, P= 0.005) and between age and serum Bcl-2 (r= 0.488, P= 0.011). Although a majority of the breast tumor tissue expresses Bcl-2, the mean Bcl-2 serum levels were not different between patient and control groups. The present data would lead us to use the Bcl-2 expression in tissue at the level of protein expression or would suggest the use of mRNA levels, but the use of serum levels would be very limited for clinical purposes.
Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran. andalib@med.mui.ac.ir
Andalib
A
Alireza
Shokohi
S
Raheleh
Rezaei
R
Abbass
Mokhtari
M
Mojgan
Mohageri
M
Mohamadreza
Mohageri
M
Gholamreza
Babazadeh
B
Shadi
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000097:blood / Q000378:metabolism*
D019253:Proto-Oncogene Proteins c-bcl-2